Volume Alert - CANF 3.79 Can-Fite Biopharma Ltd Sp
Post# of 88
Posted On: 11/19/2014 1:09:45 PM
Volume Alert - CANF 3.79 Can-Fite Biopharma Ltd Sponsore $CANF Hit a high today of 3.85 Closing the day 10:30 at 3.79 +0.79 +26.33% With a day low of 3.24 and a total volume of 1,748,655.
CANF Recent Posts: http://investorshangout.com/Can-Fite-Biopharm...ANF-88432/
CANF Can-Fite Biopharma Ltd Sponsore Recent Headline News
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 13 mins ago
CLUB: 6.06 (+0.51), LEJU: 12.30 (-1.86), ANV: 1.77 (-0.27), SSI: 18.75 (+3.01), ROX: 1.57 (-0.21), CLF: 8.74 (-1.47), BIND: 8.55 (-2.00), NADL: 3.29 (-0.68), CSTM: 17.40 (-3.57), VRML: 1.50 (+0.13), WTT: 2.62 (-0.29), CANF: 3.93 (+0.93), DL: 17.97 (+3.00), BAMM: 1.79 (+0.22), RELV: 1.32 (+0.13), SNCR: 42.75 (-4.86), ATLC: 2.64 (+0.33), AGIO: 96.11 (+12.30), BBLU: 1.08 (-0.11), OPLK: 24.17 (+2.92)
Small Cap IR Initiates Coverage of Can-Fite Biopharma: Newly Discovered Late Clinical Stage BioPharma Vendor with Potentially Revolutionary Breakthroughs
PR Newswire - Wed Nov 19, 6:30AM CST
Analyst report by Small Cap IR - Can-Fite BioPharma Ltd. (NYSEMKT: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion markets in the treatment of inflammatory diseases, cancer, sexual dysfunction, and ophthalmic indications. The Company is conducting Phase I, II and III clinical trials for numerous indications in the U.S., Europe and Israel. Can-Fite currently maintains 14 patent families that include 74 international patents issued and pending and its science is well-founded with articles in 48 peer reviewed journals.
CANF: 3.93 (+0.93)
Can-Fite shows some life
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 12:05PM CST
CANF: 3.93 (+0.93)
Can-Fite Near-Term Milestones Timetable for 2014/2015
PR Newswire - Tue Nov 18, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced several upcoming and near-term milestones on its CF101 and CF102 indications for liver cancer, rheumatoid arthritis, psoriasis, glaucoma and the development of a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).
CANF: 3.93 (+0.93)
Can-Fite Announces Special General Meeting of Shareholders to Elect External Director
PR Newswire - Mon Nov 17, 4:48PM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it is convening a Special General Meeting of Shareholders on Wednesday, December 24, 2014 at 10:00 a.m. (Israel time) at Can-Fite's offices located at 10 Bareket Street, Petach Tikva, Israel. The record date for shareholders entitled to vote at the meeting is close of business on November 26, 2014.
CANF: 3.93 (+0.93)
Can-Fite CEO Dr. Pnina Fishman to Present Recently Released Positive Data from its Rheumatoid Arthritis Phase IIb Study at the 2014 American College of Rheumatology Annual Meeting
PR Newswire - Thu Nov 13, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that the Company's CEO, Dr. Pnina Fishman, will present at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP)'s 2014 Annual Meeting. The meeting will take place in Boston, Massachusetts, from November 14-19, 2014.
CANF: 3.93 (+0.93)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 3.93 (+0.93), JNJ: 108.26 (-0.57), IDRA: 2.55 (+0.07), DERM: 16.03 (-0.26), MRK: 59.52 (-0.37), PFE: 30.32 (-0.27), AZN: 75.48 (+1.50), AMGN: 162.57 (+0.33), GSK: 46.40 (+0.12), HSP: 58.66 (-1.06), NVS: 95.84 (+0.26), CELG: 107.59 (+0.81)
Can-Fite to Participate in BIO-Europe International Partnering Conference
PR Newswire - Thu Oct 30, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that the Company's CEO, Dr. Pnina Fishman and its Director of Business Development, Dr. Sari Fishman, will participate in approximately 40 scheduled one-on-one meetings with potential industry partners at BIO-Europe® in Frankfurt, Germany on November 3 to 5, 2014.
CANF: 3.93 (+0.93)
Ad Comm backs approval of secukinumab
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 6:32AM CDT
CANF: 3.93 (+0.93), JNJ: 108.26 (-0.57), IDRA: 2.55 (+0.07), DERM: 16.03 (-0.26), PFE: 30.32 (-0.27), AZN: 75.48 (+1.50), MRK: 59.52 (-0.37), AMGN: 162.57 (+0.33), HSP: 58.66 (-1.06), CELG: 107.59 (+0.81), NVS: 95.84 (+0.26)
Ad Comm meeting approaches for Novartis' psoriasis therapy candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 10:46AM CDT
CANF: 3.93 (+0.93), JNJ: 108.26 (-0.57), IDRA: 2.55 (+0.07), DERM: 16.03 (-0.26), PFE: 30.32 (-0.27), AZN: 75.48 (+1.50), MRK: 59.52 (-0.37), AMGN: 162.57 (+0.33), HSP: 58.66 (-1.06), CELG: 107.59 (+0.81), NVS: 95.84 (+0.26)
Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:32AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise more than 6% on the day.
CANF: 3.93 (+0.93), AMPE: 3.57 (+0.10), CEMP: 13.45 (-0.48), CORT: 2.98 (-0.07)
Can-Fite CEO Dr. Pnina Fishman to Co-Chair and Present at the 19th World Congress on Advances in Oncology's Cancer Therapeutics Session
PR Newswire - Tue Oct 07, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the Company's CEO, Dr. Pnina Fishman, will co-chair the Cancer Therapeutics session of the 19th World Congress on Advances in Oncology. The conference will take place in Athens, Greece, from October 9-11, 2014.
CANF: 3.93 (+0.93)
U.S. Patent and Trademark Office Issues Can-Fite Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
PR Newswire - Tue Sep 30, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the United States Patent and Trademark Office has issued a patent to the Company which covers its drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery. The issued patent # 8,846,635 is titled, "Method for inducing hepatocyte proliferation and uses thereof." Can-Fite has recently been granted a patent for this technology in Japan and the European Union.
CANF: 3.93 (+0.93)
Can-Fite Files June 30, 2014 Interim Financial Statements
PR Newswire - Wed Sep 17, 2:02PM CDT
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has filed its unaudited interim consolidated financial statements as of June 30, 2014 and an operating and financial review for such period with the U.S. Securities and Exchange Commission. The filing can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov.
CANF: 3.93 (+0.93)
Can Fite's Drug CF101 is Presented in Scientific Journal as One of Four Small Molecule Drugs for the Treatment of Psoriasis
PR Newswire - Wed Sep 17, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that an article titled, "New Drugs and Treatment Targets in Psoriasis," published in the peer-reviewed scientific journal Acta Derm Venereologica, cites the Company's CF101 as a potential treatment for psoriasis. The article was written by researchers at the Department of Dermato-allergology, Gentofte Hospital, University of Copenhagen, Denmark. To read the article in full, please visit: Acta Derm Venereologica.
CANF: 3.93 (+0.93)
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
CANF: 3.93 (+0.93), ECYT: 6.41 (+0.03), ENZ: 4.49 (-0.17), PFE: 30.33 (-0.26), ABBV: 65.67 (-0.38), XOMA: 4.23 (+0.17), NVS: 95.84 (+0.26)
Can-Fite BioPharma receives Japanese patent for liver regeneration clinical stage drug candidate CF102
M2 - Mon Sep 08, 5:27AM CDT
Biotechnology company Can-Fite BioPharma (NYSE MKT:CANF) (Tel Aviv:CFBI.TA) reported on Friday the receipt of the patent, titled 'Method for inducing hepatocyte proliferation and uses thereof', from the Japanese Patent Office.
CANF: 3.93 (+0.93)
Can-Fite Issued Japanese Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
PR Newswire - Fri Sep 05, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the issuance of Patent No. 2010-529501, titled, "Method for inducing hepatocyte proliferation and uses thereof," by the Japanese Patent Office. The patent covers Can-Fite's clinical stage drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery or other injury via inhibition of pro-apoptotic proteins, resulting in liver repair. A European Patent (No. 2227234) for this technology was issued earlier this year in the European Union.
CANF: 3.93 (+0.93)
Can-Fite posts lower loss of USD3.59m for first six months 2014
M2 - Wed Sep 03, 7:21AM CDT
Biotechnology company Can-Fite BioPharma (NYSE MKT:CANF) (Tel Aviv:CFBI.TA) on Tuesday declared a loss of USD3.59m for the six months ended 30 June 2014.
CANF: 3.93 (+0.93)
CANF Recent Posts: http://investorshangout.com/Can-Fite-Biopharm...ANF-88432/
CANF Can-Fite Biopharma Ltd Sponsore Recent Headline News
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 13 mins ago
CLUB: 6.06 (+0.51), LEJU: 12.30 (-1.86), ANV: 1.77 (-0.27), SSI: 18.75 (+3.01), ROX: 1.57 (-0.21), CLF: 8.74 (-1.47), BIND: 8.55 (-2.00), NADL: 3.29 (-0.68), CSTM: 17.40 (-3.57), VRML: 1.50 (+0.13), WTT: 2.62 (-0.29), CANF: 3.93 (+0.93), DL: 17.97 (+3.00), BAMM: 1.79 (+0.22), RELV: 1.32 (+0.13), SNCR: 42.75 (-4.86), ATLC: 2.64 (+0.33), AGIO: 96.11 (+12.30), BBLU: 1.08 (-0.11), OPLK: 24.17 (+2.92)
Small Cap IR Initiates Coverage of Can-Fite Biopharma: Newly Discovered Late Clinical Stage BioPharma Vendor with Potentially Revolutionary Breakthroughs
PR Newswire - Wed Nov 19, 6:30AM CST
Analyst report by Small Cap IR - Can-Fite BioPharma Ltd. (NYSEMKT: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion markets in the treatment of inflammatory diseases, cancer, sexual dysfunction, and ophthalmic indications. The Company is conducting Phase I, II and III clinical trials for numerous indications in the U.S., Europe and Israel. Can-Fite currently maintains 14 patent families that include 74 international patents issued and pending and its science is well-founded with articles in 48 peer reviewed journals.
CANF: 3.93 (+0.93)
Can-Fite shows some life
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 12:05PM CST
CANF: 3.93 (+0.93)
Can-Fite Near-Term Milestones Timetable for 2014/2015
PR Newswire - Tue Nov 18, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced several upcoming and near-term milestones on its CF101 and CF102 indications for liver cancer, rheumatoid arthritis, psoriasis, glaucoma and the development of a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).
CANF: 3.93 (+0.93)
Can-Fite Announces Special General Meeting of Shareholders to Elect External Director
PR Newswire - Mon Nov 17, 4:48PM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it is convening a Special General Meeting of Shareholders on Wednesday, December 24, 2014 at 10:00 a.m. (Israel time) at Can-Fite's offices located at 10 Bareket Street, Petach Tikva, Israel. The record date for shareholders entitled to vote at the meeting is close of business on November 26, 2014.
CANF: 3.93 (+0.93)
Can-Fite CEO Dr. Pnina Fishman to Present Recently Released Positive Data from its Rheumatoid Arthritis Phase IIb Study at the 2014 American College of Rheumatology Annual Meeting
PR Newswire - Thu Nov 13, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that the Company's CEO, Dr. Pnina Fishman, will present at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP)'s 2014 Annual Meeting. The meeting will take place in Boston, Massachusetts, from November 14-19, 2014.
CANF: 3.93 (+0.93)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 3.93 (+0.93), JNJ: 108.26 (-0.57), IDRA: 2.55 (+0.07), DERM: 16.03 (-0.26), MRK: 59.52 (-0.37), PFE: 30.32 (-0.27), AZN: 75.48 (+1.50), AMGN: 162.57 (+0.33), GSK: 46.40 (+0.12), HSP: 58.66 (-1.06), NVS: 95.84 (+0.26), CELG: 107.59 (+0.81)
Can-Fite to Participate in BIO-Europe International Partnering Conference
PR Newswire - Thu Oct 30, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that the Company's CEO, Dr. Pnina Fishman and its Director of Business Development, Dr. Sari Fishman, will participate in approximately 40 scheduled one-on-one meetings with potential industry partners at BIO-Europe® in Frankfurt, Germany on November 3 to 5, 2014.
CANF: 3.93 (+0.93)
Ad Comm backs approval of secukinumab
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 6:32AM CDT
CANF: 3.93 (+0.93), JNJ: 108.26 (-0.57), IDRA: 2.55 (+0.07), DERM: 16.03 (-0.26), PFE: 30.32 (-0.27), AZN: 75.48 (+1.50), MRK: 59.52 (-0.37), AMGN: 162.57 (+0.33), HSP: 58.66 (-1.06), CELG: 107.59 (+0.81), NVS: 95.84 (+0.26)
Ad Comm meeting approaches for Novartis' psoriasis therapy candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 10:46AM CDT
CANF: 3.93 (+0.93), JNJ: 108.26 (-0.57), IDRA: 2.55 (+0.07), DERM: 16.03 (-0.26), PFE: 30.32 (-0.27), AZN: 75.48 (+1.50), MRK: 59.52 (-0.37), AMGN: 162.57 (+0.33), HSP: 58.66 (-1.06), CELG: 107.59 (+0.81), NVS: 95.84 (+0.26)
Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:32AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise more than 6% on the day.
CANF: 3.93 (+0.93), AMPE: 3.57 (+0.10), CEMP: 13.45 (-0.48), CORT: 2.98 (-0.07)
Can-Fite CEO Dr. Pnina Fishman to Co-Chair and Present at the 19th World Congress on Advances in Oncology's Cancer Therapeutics Session
PR Newswire - Tue Oct 07, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the Company's CEO, Dr. Pnina Fishman, will co-chair the Cancer Therapeutics session of the 19th World Congress on Advances in Oncology. The conference will take place in Athens, Greece, from October 9-11, 2014.
CANF: 3.93 (+0.93)
U.S. Patent and Trademark Office Issues Can-Fite Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
PR Newswire - Tue Sep 30, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the United States Patent and Trademark Office has issued a patent to the Company which covers its drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery. The issued patent # 8,846,635 is titled, "Method for inducing hepatocyte proliferation and uses thereof." Can-Fite has recently been granted a patent for this technology in Japan and the European Union.
CANF: 3.93 (+0.93)
Can-Fite Files June 30, 2014 Interim Financial Statements
PR Newswire - Wed Sep 17, 2:02PM CDT
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has filed its unaudited interim consolidated financial statements as of June 30, 2014 and an operating and financial review for such period with the U.S. Securities and Exchange Commission. The filing can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov.
CANF: 3.93 (+0.93)
Can Fite's Drug CF101 is Presented in Scientific Journal as One of Four Small Molecule Drugs for the Treatment of Psoriasis
PR Newswire - Wed Sep 17, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that an article titled, "New Drugs and Treatment Targets in Psoriasis," published in the peer-reviewed scientific journal Acta Derm Venereologica, cites the Company's CF101 as a potential treatment for psoriasis. The article was written by researchers at the Department of Dermato-allergology, Gentofte Hospital, University of Copenhagen, Denmark. To read the article in full, please visit: Acta Derm Venereologica.
CANF: 3.93 (+0.93)
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
CANF: 3.93 (+0.93), ECYT: 6.41 (+0.03), ENZ: 4.49 (-0.17), PFE: 30.33 (-0.26), ABBV: 65.67 (-0.38), XOMA: 4.23 (+0.17), NVS: 95.84 (+0.26)
Can-Fite BioPharma receives Japanese patent for liver regeneration clinical stage drug candidate CF102
M2 - Mon Sep 08, 5:27AM CDT
Biotechnology company Can-Fite BioPharma (NYSE MKT:CANF) (Tel Aviv:CFBI.TA) reported on Friday the receipt of the patent, titled 'Method for inducing hepatocyte proliferation and uses thereof', from the Japanese Patent Office.
CANF: 3.93 (+0.93)
Can-Fite Issued Japanese Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
PR Newswire - Fri Sep 05, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the issuance of Patent No. 2010-529501, titled, "Method for inducing hepatocyte proliferation and uses thereof," by the Japanese Patent Office. The patent covers Can-Fite's clinical stage drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery or other injury via inhibition of pro-apoptotic proteins, resulting in liver repair. A European Patent (No. 2227234) for this technology was issued earlier this year in the European Union.
CANF: 3.93 (+0.93)
Can-Fite posts lower loss of USD3.59m for first six months 2014
M2 - Wed Sep 03, 7:21AM CDT
Biotechnology company Can-Fite BioPharma (NYSE MKT:CANF) (Tel Aviv:CFBI.TA) on Tuesday declared a loss of USD3.59m for the six months ended 30 June 2014.
CANF: 3.93 (+0.93)
(0)
(0)Can-Fite Biopharma Ltd. (CANF) Stock Research Links
Scroll down for more posts ▼